BioSpace News Archive

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conference.

BIOLASE, Inc., the global leader in dental lasers, encourages stockholders to vote “FOR” the amendment to the BIOLASE, Inc.

MiNK Therapeutics, today announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat hosted by Evercore on December 1st, 2021, at 8:25 AM ET.

Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its IND for a phase I-II, randomized, double-blind, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in children with Pitt Hopkins Syndrome, a rare neurogenetic disorder that features autistic traits.

Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, today announced financial results for the quarter ended September 30, 2021.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

Celanese Corporation and Mitsubishi Chemical Advanced Materials announced a joint collaboration to further develop mechanical recycling solutions for both post-industrial and post-consumer sources of polyoxymethylene, also known as acetal copolymer, to meet the requests from customers seeking recycled content options and carbon dioxide reductions while still maintaining product consistency, quality and performance.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the mainland China market.

Certara, Inc., a global leader in biosimulation, announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders at a price to the public of $31.00 per share.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), today announced that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.